| Identification | Back Directory | [Name]
3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- | [CAS]
2055357-64-5 | [Synonyms]
Nesuparib
3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- | [Molecular Formula]
C23H24N6O | [MOL File]
2055357-64-5.mol | [Molecular Weight]
400.48 |
| Chemical Properties | Back Directory | [Boiling point ]
692.8±55.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
13.75±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Nesuparib (JPI-547) is an orally active PARP 1/2 and Tankyrase 1/2 inhibitor involved in the Wnt/β-catenin pathway. Nesuparib can induce cell cycle arrest and apoptosis and has anti-tumor activity. Nesuparib can be used to study cancer, neurological diseases and cardiovascular diseases[1][1][3]. | [IC 50]
PARP1; PARP2 | [References]
[1] Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same. Patent WO2016200101A2.
[2] Im S A , et al.A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.[J].Journal of Clinical Oncology, 2021, 39(15_suppl):3113-3113.
[3] Oh K S, et al. JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction[J]. Cancer Research, 2023, 83(7_Supplement): 4496-4496. |
|
|